{"schema_version":"secwatch.filing_event.v1","accession":"0001285550-23-000010","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2023-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.224625+00:00","generated_at":"2026-06-20T16:26:28.171601+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ClearPoint Neuro Q4 revenue $5.2M (+21%); FY2022 revenue $20.6M (+26%) missing guidance; FY2023 guide $25-27M","bullets":["Preliminary Q4 2022 revenue $5.2M (+21% YoY); biologics/drug delivery $2.3M (+37%); functional neurosurgery $2.3M (+7%).","Full year 2022 revenue $20.6M (+26% YoY), below guidance of $21-22M; cash burn $3.0M in Q4; cash $37.5M at year-end.","FY2023 revenue guidance $25-27M (22-31% growth); backlog at highest level; CEO cites Q4 timing issues.","Key upcoming milestones: PTC BLA submission for Upstaza, PRISM laser system commercial launch, 10 new centers, 8 FDA submissions.","Added multiple new biologics/drug delivery partners, total >50; 11 new centers installed in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001285550-23-000010","json":"https://secwatch.observer/filing/0001285550-23-000010.json","markdown":"https://secwatch.observer/filing/0001285550-23-000010.md","text":"https://secwatch.observer/filing/0001285550-23-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000010/0001285550-23-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000010/clpt-20230111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T16:26:28.171601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c6a6c742a2974d01920e7a0277d460805d9bfb38","claim":"ClearPoint Neuro, Inc. reported the fourth fiscal quarter ended December 31, 2022 results: revenue $5.2 million.","evidence_excerpt":"financial results for its fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Preliminary Unaudited Financial Highlights • Preliminary unaudited revenue of $5.2 million, a 21% year-over-year increase; • Increased biologics and drug delivery revenue to $2.3 million, a 37% year-over-year increase; • Increased functional neurosurgery products and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000010/0001285550-23-000010-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth fiscal quarter ended December 31, 2022"},{"label":"Revenue","value":"$5.2 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"f8a8facae243510aa346ae9c55d8179748afbea6","claim":"ClearPoint Neuro, Inc. reported full year ended December 31, 2022 results: revenue $20.6 million. Guidance initiated.","evidence_excerpt":"cash equivalents, and short-term investments at December 31, 2022. Full Year 2022 Preliminary Unaudited Financial Highlights • Achieved preliminary unaudited record revenue of $20.6 million, a 26% year-over-year increase, versus most recent guidance of $21.0 - $22.0 million; • Increased biologics and drug delivery revenue to $9.1 million, a 34% year-over-year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000010/0001285550-23-000010-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2022"},{"label":"Revenue","value":"$20.6 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}